The article reviews the genetic basis of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It highlights the identification of key genes involved in ALS pathogenesis, including SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72, and PFN1. These genes account for a significant proportion of familial ALS cases and some sporadic cases. Recent advances in genome-wide association studies (GWAS) have identified additional risk loci, such as UNC13A and 1q32, which may contribute to ALS susceptibility. The discovery of the C9ORF72 hexanucleotide repeat expansion has been particularly significant, as it is a major cause of both familial and sporadic ALS. This expansion is associated with a range of clinical features, including frontotemporal dementia and other neurodegenerative conditions. The article also discusses the genetic overlap between ALS and other neurodegenerative diseases, such as frontotemporal dementia and Parkinson's disease. It emphasizes the importance of understanding the genetic heterogeneity of ALS and the potential for targeted therapies, such as antisense oligonucleotides, to treat patients with specific genetic mutations. The review concludes that ongoing research in ALS genetics is crucial for developing effective treatments and improving our understanding of this complex disease.The article reviews the genetic basis of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It highlights the identification of key genes involved in ALS pathogenesis, including SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72, and PFN1. These genes account for a significant proportion of familial ALS cases and some sporadic cases. Recent advances in genome-wide association studies (GWAS) have identified additional risk loci, such as UNC13A and 1q32, which may contribute to ALS susceptibility. The discovery of the C9ORF72 hexanucleotide repeat expansion has been particularly significant, as it is a major cause of both familial and sporadic ALS. This expansion is associated with a range of clinical features, including frontotemporal dementia and other neurodegenerative conditions. The article also discusses the genetic overlap between ALS and other neurodegenerative diseases, such as frontotemporal dementia and Parkinson's disease. It emphasizes the importance of understanding the genetic heterogeneity of ALS and the potential for targeted therapies, such as antisense oligonucleotides, to treat patients with specific genetic mutations. The review concludes that ongoing research in ALS genetics is crucial for developing effective treatments and improving our understanding of this complex disease.